UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2022.

Commission File Number: 001-40627

SOPHiA GENETICS SA
(Exact name of registrant as specified in its charter)

Rue du Centre 172
CH-1025 Saint-Sulpice
Switzerland
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☑ Form 20-F
☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On June 15, 2022, SOPHiA GENETICS SA (the “Company”) held its annual general meeting. The final results of each of the agenda items submitted to a vote of the shareholders are below:

- **Item 1: 2021 Management Report, Annual Financial Statements and Consolidated Financial Statements, Auditors’ Reports.** The shareholders approved the 2021 Management Report, the Annual Financial Statements and the Consolidated Financial Statements for the fiscal year 2021 and took note of the Auditors’ Reports. The shareholders approved this item with 24,126,190 votes (99.95% of all ordinary shares represented) in favor, 1,514 votes (0.01%) against and 9,695 (0.04%) abstentions.

- **Item 2: Discharge of the members of the Board of Directors and the Executive Committee.** The shareholders approved the discharge of the members of the Board of Directors and the Executive Committee from liability for the fiscal year 2021. The shareholders approved this item with 20,933,769 votes (99.75% of all ordinary shares represented) in favor, 49,795 votes (0.23%) against and 3,935 (0.02%) abstentions.

- **Item 3: Appropriation of 2021 Financial Result.** The shareholders approved that the loss for the year 2021 in the amount of CHF 62,506,860 be carried forward, resulting in total loss of CHF 181,995,748 to be carried forward. The shareholders approved this item with 24,112,204 votes (99.90% of all ordinary shares represented) in favor, 19,569 votes (0.08%) against and 5,626 (0.00%) abstentions.

- **Item 4: Increase and Renewal of Authorized Share Capital.** The shareholders approved the increase and renewal of the Company’s Authorized Share Capital by CHF 235,928.75, by amending Article 4a, Paragraph 1 of the Company’s Articles of Association. The shareholders approved this item with 18,916,292 votes (78.37% of all ordinary shares represented) in favor, 5,219,391 votes (21.62%) against and 1,716 (0.01%) abstentions.

- **Item 5: Increase of Conditional Share Capital for Employee Participation.** The shareholders approved the increase of the Company’s Conditional Share Capital for Employee Participation by CHF 125,000, by amending Article 4b, Paragraph 1 of the Company’s Articles of Association. The shareholders approved this item with 19,865,110 votes (82.30% of all ordinary shares represented) in favor, 4,271,589 votes (17.70%) against and 700 (0.00%) abstentions.

- **Item 6: Increase of Conditional Share Capital for Financing, Acquisitions and Other Purposes.** The shareholders approved the increase of the Company’s Conditional Share Capital for Employee Participation by CHF 211,982.10, by amending Article 4c, Paragraph 1 of the Company’s Articles of Association. The shareholders approved this item with 18,921,004 votes (78.39% of all ordinary shares represented) in favor, 5,215,895 votes (21.61%) against and 500 (0.00%) abstentions.

- **Item 7: Amendments to Articles of Association.** The shareholders approved the amendment of Article 15 of the Company’s Articles of Association to increase the maximum size of the Board of Directors to 8 members. The shareholders approved this item with 24,055,690 votes (99.66% of all ordinary shares represented) in favor, 1,514 votes (0.01%) against and 9,695 (0.04%) abstentions.

- **Item 8: Re-election of the Chairman; election and re-election of the Members of the Board of Directors.** The shareholders approved the re-election of the current members of the Board of Directors, including the Chairman, for a term of office until the completion of the 2023 Annual General Meeting and the election of Jean-Michel Cosséry as a new member of the Board of Directors for a term of office until the completion of the 2023 Annual General Meeting.
  - The shareholders approved the re-election of Troy Cox with 23,777,672 votes (98.51% of all ordinary shares represented) in favor, 353,052 votes (1.46%) against and 6,675 (0.03%) abstentions.
  - The shareholders approved the re-election of Jurgi Camblong with 24,071,483 votes (99.73% of all ordinary shares represented) in favor, 53,101 votes (0.22%) against and 12,815 (0.05%) abstentions.
  - The shareholders approved the re-election of Tomer Berkovitz with 24,062,539 votes (99.69% of all ordinary shares represented) in favor, 5,465 votes (0.02%) against and 69,395 (0.29%) abstentions.
  - The shareholders approved the re-election of Kathy Hibbs with 23,651,757 votes (97.99% of all ordinary shares represented) in favor, 414,667 votes (1.72%) against and 70,975 (0.29%) abstentions.
  - The shareholders approved the re-election of Didier Hirsch with 23,716,116 votes (98.25% of all ordinary shares represented) in favor, 349,788 votes (1.45%) against and 71,495 (0.30%) abstentions.
  - The shareholders approved the re-election of Vincent Ossipow with 23,576,095 votes (99.67% of all ordinary shares represented) in favor, 489,809 votes (2.03%) against and 71,495 (0.30%) abstentions.
  - The shareholders approved the re-election of Milton Silva-Craig with 24,062,099 votes (99.68% of all ordinary shares represented) in favor, 3,905 votes (0.02%) against and 71,495 (0.30%) abstentions.
  - The shareholders approved the election of Jean-Michel Cosséry with 23,996,611 votes (99.41% of all ordinary shares represented) in favor, 85,813 votes (0.36%) against and 54,975 (0.23%) abstentions. Below is Dr. Cosséry’s biography:

Jean-Michel Cosséry, age 63, Ph.D., Pharm.D., M.B.A., has been a member of our board of directors since June 2022. From 2012 to 2018, Dr. Cosséry served in various senior leadership positions at Eli Lilly and Company, including as Vice President, North America Oncology, as well as Vice President and Managing Director of Lilly UK and Northern Europe. Prior to that, he served as Vice President and Chief Marketing Officer of GE Healthcare as well as in senior positions at Novartis International AG and Serono (now Merck (Schweiz) AG). Dr. Cosséry serves on the board of directors of Malin Corporation plc, Exact Therapeutics AS, Diurnal PLC, and Eracal Therapeutics Ltd., and previously served on the board of directors of ABPI (UK) LIMITED, Immunocore Holdings Limited, and Kymab Ltd and as chairman of the board of directors of the American Pharmaceutical Group in the UK. Dr. Cosséry holds an M.B.A. from the Rotterdam School of Management, a Ph.D. with honors in nuclear chemistry and neurobiology from Paris Sud University, and a Pharm.D. with honors in pharmacology from Paris Sud University.
There are no family relationships between Dr. Cosséry or any of our directors or executive officers. Our board of directors has determined that Dr. Cosséry is an independent director within the meaning of applicable Nasdaq standards.
Item 9. Re-election of the members of the Compensation Committee. The shareholders approved the re-election of Milton Silva-Craig and Vincent Ossipow and the election of Kathy Hibbs and Jean-Michel Cosséry as members of the Compensation Committee, each for a term of office until the completion of the 2023 Annual General Meeting.

- The shareholders approved the re-election of Milton Silva-Craig with 23,678,843 votes (98.10% of all ordinary shares represented) in favor, 300,391 votes (1.24%) against and 158,165 (0.66%) abstentions.

- The shareholders approved the re-election of Vincent Ossipow with 23,613,099 votes (97.82% of all ordinary shares represented) in favor, 366,135 votes (1.52%) against and 158,165 (0.66%) abstentions.

- The shareholders approved the election of Kathy Hibbs with 23,565,165 votes (97.63% of all ordinary shares represented) in favor, 414,589 votes (1.72%) against and 157,645 (0.65%) abstentions.

- The shareholders approved the election of Jean-Michel Cosséry with 23,910,093 votes (99.06% of all ordinary shares represented) in favor, 71,847 votes (0.30%) against and 155,459 (0.64%) abstentions.

Item 10. Re-election of the Independent Proxy. The shareholders approved the re-election of Martin Habs, Esq., notary public, in Lausanne, Switzerland, as independent proxy for a term of office until the completion of the 2023 Annual General Meeting. The shareholders approved this item with 24,125,320 votes (99.95% of all ordinary shares represented) in favor, 2,050 votes (0.01%) against and 10,029 (0.04%) abstentions.

Item 11. Re-election of the Statutory Auditor. The shareholders approved the re-election of PricewaterhouseCoopers SA as the statutory auditors for the fiscal year 2022. The shareholders approved this item with 24,129,500 votes (99.97% of all ordinary shares represented) in favor, 820 votes (0.00%) against and 7,079 (0.03%) abstentions.

Item 12. Approval of the Compensation of the Board of Directors and the Executive Board. The shareholders approved a maximum aggregate amount of compensation for the members of the Board of Directors of USD 1,766,000 for the period from the 2022 Annual General Meeting to the 2023 Annual General Meeting, a maximum aggregate amount of fixed compensation for the members of the Executive Board of USD 2,400,000 for the fiscal year 2023 and a maximum aggregate amount of variable compensation for the members of the Executive Board of USD 5,900,000 for the current fiscal year 2022.

- The shareholders approved the maximum aggregate amount of compensation for members of the Board of Directors with 19,651,130 votes (81.42% of all ordinary shares represented) in favor, 4,483,324 votes (18.57%) against and 2,945 (0.01%) abstentions.

- The shareholders approved the maximum aggregate amount of fixed compensation for members of the Executive Board with 23,934,778 votes (99.16% of all ordinary shares represented) in favor, 194,041 votes (0.80%) against and 8,580 (0.04%) abstentions.

- The shareholders approved the maximum aggregate amount of variable compensation for members of the Executive Board with 20,660,776 votes (85.59% of all ordinary shares represented) in favor, 3,293,913 votes (13.65%) against and 182,710 (0.76%) abstentions.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SOPHiA GENETICS SA

Date: June 15, 2022

By: /s/ Daan van Well
Name: Daan van Well
Title: Chief Legal Officer
<table>
<thead>
<tr>
<th>Exhibit No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>99.1</td>
<td>Amended Articles of Association</td>
</tr>
<tr>
<td>99.2</td>
<td>Press release dated June 15, 2022</td>
</tr>
</tbody>
</table>
ARTICLES OF ASSOCIATION
OF SOPHIA GENETICS SA

STATUTS
DE SOPHIA GENETICS SA
Section 1
Name, registered office, purpose and duration of the Company

Article 1
Under the name SOPHiA GENETICS SA (the Company) exists a corporation with its registered office in Saint-Sulpice, Canton of Vaud, governed by these articles of association (the Articles of Association) and the Swiss Code of Obligations (CO).

Article 2
1 The Company's purpose is the management, preservation and storage of archives of all types, in particular computer and paper archives, as well as the design, development, maintenance, sale and lease of systems, products and services in connection therewith; the development, management and transfer of licenses and franchise agreements in connection therewith, as well as the preservation and archiving of data in the genetic field. The Company may carry out any financial, commercial or industrial activities, in movable or real property, in direct or indirect connection with its purpose.

2 The Company may open branch offices and subsidiaries in Switzerland and abroad. It may also acquire participations or otherwise invest in other companies in Switzerland and abroad.

3 The Company may acquire, hold, manage, mortgage, exploit and sell real estate and intellectual property rights in Switzerland and abroad and may also finance other companies.

Purpose

Section 1
Raison sociale, siège, but et durée de la Société

Article 1
Sous la raison sociale SOPHiA GENETICS SA (la Société) existe une société anonyme avec siège à Saint-Sulpice, Canton de Vaud, régie par les présents statuts (les Statuts) et le Code suisse des obligations (CO).

Article 2
1 La Société a pour but la gestion, la conservation et l'entreposage d'archives de toute nature, notamment d'archives informatiques et de papiers ainsi que la conception, la réalisation, la maintenance, la vente et la location de systèmes, produits et services s'y rapportant; le développement, la gestion et le transfert de licences et contrats de franchise y relatives, ainsi que la conservation et l'archivage de données dans le domaine de la génétique. La Société peut exercer toute activité financière, commerciale ou industrielle, mobilière ou immobilière, en rapport direct ou indirect avec son but.

2 La Société peut constituer des succursales et des filiales en Suisse et à l'étranger et participer à ou investir autrement dans d'autres entreprises en Suisse et à l'étranger.

3 La Société peut acquérir, détenir, gérer, gager, mettre en valeur et aliéner des immeubles et des droits de propriété intellectuelle en Suisse et à l'étranger, ainsi que financer d'autres sociétés.
### Article 3
The duration of the Company shall be unlimited.

**Durée**
La durée de la Société est illimitée.

### Section 2

#### Share capital, shares, restrictions of transferability

**Article 4**
The share capital of the Company is CHF 3,319,908.20 and is divided into 66,398,164 fully paid in registered shares with a par value of CHF 0.05 each.

**Capital-actions**
Le capital-actions de la Société est de CHF 3'319'908.20 et est divisé en 66'398'164 actions nominatives entièrement libérées d'une valeur nominale de CHF 0.05 chacune.

**Article 4a**
1. The Board of Directors shall be authorized to increase the share capital at any time, including in connection with an intended takeover, until June 14, 2024 at the latest, by a maximum amount of CHF 1,659,954.10 by issuing a maximum of 33,199,082 fully paid in registered shares with a par value of CHF 0.05 each. Increases in partial amounts shall be permissible.

2. The subscription and acquisition of the new shares, as well as any subsequent transfer of the shares, shall be subject to the restrictions pursuant to article 6 of these Articles of Association.

**Article 4a**
1. Le Conseil d'Administration est autorisé à augmenter le capital-actions d'un montant maximum de CHF 1'659'954.10, en tout temps, y compris en lien avec une future offre publique d'acquisition, mais jusqu'au 14 juin 2024 au plus tard, par l'émission d'un maximum de 33'199'082 actions nominatives d'une valeur nominale de CHF 0.05 chacune, qui doivent être intégralement libérées. Des augmentations par montants partiels sont autorisées.

2. La souscription et l'acquisition des nouvelles actions, ainsi que tout transfert ultérieur des actions, sont assujettis aux restrictions à la transmissibilité conformément à l'article 6 des Statuts.
3 The Board of Directors shall determine the issue price, the type of contribution, the date of issue, the conditions for the exercise of pre-emptive rights and the beginning date for dividend entitlement. In this regard, the Board of Directors may issue new shares by means of a firm underwriting through a financial institution, a syndicate of financial institutions or another third party and a subsequent offer of these shares to the existing shareholders or third parties (if the pre-emptive rights of the existing shareholders have been withdrawn or have not been duly exercised). The Board of Directors is entitled to permit, to restrict or to exclude the trading of pre-emptive rights. It may permit the expiration of pre-emptive rights that have not been exercised, or it may place such rights or shares as to which pre-emptive rights have been granted, but not exercised, at market conditions or may use them otherwise in the interest of the Company.

4 The Board of Directors is further authorized to withdraw or restrict pre-emptive rights of existing shareholders and to allocate such rights to third parties, the Company or any of its group companies:
   (a) if the issue price of the new shares is determined by reference to the market price; or
   (b) for raising capital in a fast and flexible manner, which would not be possible, or might only be possible with great difficulty or delays or at significantly less favorable conditions, without the exclusion of the pre-emptive rights of existing shareholders; or
   (c) for the acquisition of companies, part(s) of companies or participations, for the acquisition of products, intellectual property or licenses by or for investment projects of the Company or any of its group companies, or for the financing or refinancing of any of such transactions through a placement of shares; or
(d) for purposes of broadening the shareholder constituency of the Company in certain geographic, financial or investor markets, for purposes of the participation of strategic partners, or in connection with the listing of new shares on domestic or foreign stock exchanges; or

(e) for purposes of granting an over-allotment option (Greenshoe) or an option to subscribe for additional shares in a placement or sale of shares to the respective initial purchaser(s) or underwriter(s); or

(f) for the participation of members of the board of directors (or equivalent corporate body), members of the executive management, employees, contractors, consultants, or other persons performing services for the benefit of, the Company or any of its group companies; or

(g) following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of 15% of the share capital registered in the commercial register without having submitted to all other shareholders a takeover offer recommended by the Board of Directors; or

(h) for the defense of an actual, threatened or potential takeover bid that the Board of Directors, upon consultation with an independent financial adviser retained by it, has not recommended or will not recommend to the shareholders to accept on the basis that the Board of Directors does not find such takeover bid to be (i) financially fair to the shareholders or (ii) in the Company's interest.
Conditional share capital for employee participation

Article 4b
1 The share capital may be increased in an amount not to exceed CHF 580,000 through the issuance of up to 11,600,000 fully paid in registered shares with a par value of CHF 0.05 per share through the direct or indirect issuance of shares, options or related subscription rights to members of the board of directors (or equivalent corporate body), members of the executive management, employees, contractors or consultants of the Company or its group companies, or other persons providing services to the Company or its group companies.

2 The pre-emptive rights and advance subscription rights of the shareholders of the Company shall be excluded in connection with the issuance of any shares, options, other rights to receive shares, or subscription rights therefor. Shares, options, other rights to receive shares, or subscription rights therefor shall be issued pursuant to one or more regulations to be issued by the Board of Directors or, to the extent delegated to it, the Compensation Committee, and to the extent applicable, taking into account the compensation principles pursuant to article 28 of these Articles of Association. Shares, options, other rights to receive shares, or subscription rights therefor may be issued at a price or with an exercise price lower than the market price.

3 The direct or indirect acquisition of the new shares by persons listed in paragraph 1 of this article 4b in connection with an employee participation program, as well as any subsequent transfer of such shares, shall be subject to the restrictions of article 6 of these Articles of Association.

Capital-actions conditionnel pour la participation des employés

Article 4b
1 Le capital-actions peut être augmenté d'un montant maximum de CHF 580'000 par l'émission de 11'600'000 actions nominatives au plus, d'une valeur nominale de CHF 0.05 chacune, qui doivent être intégralement libérées, par l'émission directe ou indirecte d'actions, d'options ou de droits de souscription y relatifs, octroyés à des membres du conseil d'administration (ou d'un organe équivalent), des membres de la direction, des employés, des co-contractants ou des consultants de la Société ou de l'une des sociétés du groupe, ou d'autres personnes exerçant des services au bénéfice de la Société ou de l'une des sociétés du groupe.

2 Le droit de souscription préférentiel ainsi que le droit de souscription préalable des actionnaires de la Société sont exclus en relation avec l'émission de toutes actions, options, autres droits à recevoir des actions ou des droits de souscription qui y sont attachés. L'émission d'actions, d'options, d'autres droits à recevoir des actions ou des droits de souscription qui y sont attachés est faite selon un ou plusieurs règlements adoptés par le Conseil d'Administration ou le Comité de Rémunération, dans la mesure où cette compétence lui a été déléguée, et, le cas échéant, en tenant compte des principes de rémunération selon l'article 28 des Statuts. L'émission d'actions, d'options, d'autres droits à recevoir des actions ou des droits de souscription qui y sont attachés peut se faire à un prix ou avec un prix d'exercice en-dessous du prix du marché.

3 L'acquisition directe ou indirecte de nouvelles actions par des personnes mentionnées à l'alinéa 1 du présent article 4b dans le cadre d'un programme de participation des collaborateurs, ainsi que le transfert subséquent de ces actions, sont assujettis aux restrictions à la transmissibilité conformément à l'article 6 des Statuts.
Conditional share capital for financing, acquisitions and other purposes

Article 4c

1. The share capital may be increased including in connection with an intended takeover in an amount not to exceed CHF 1,079,954.10 through the issuance of up to 21,599,082 fully paid in registered shares with a par value of CHF 0.05 per share through the exercise or mandatory exercise of conversion, exchange, option, warrant or similar rights or obligations for the subscription of shares granted to shareholders or third parties on a stand-alone basis or in connection with bonds, notes, options, warrants or other securities or contractual obligations of the Company or any of its group companies (collectively, the Financial Instruments).

2. The pre-emptive rights of shareholders shall be excluded for the exercise of any Financial Instruments in connection with the issuance of shares. The then-current owners of such Financial Instruments shall be entitled to acquire the new shares issued upon conversion, exchange or exercise of any Financial Instruments. The main conditions of the Financial Instruments shall be determined by the Board of Directors.

3. The Board of Directors shall be authorized to restrict or withdraw advance subscription rights of shareholders in connection with the issuance of Financial Instruments by the Company or one of its group companies (1) if the issuance is for purposes of financing or refinancing, or the payment for, the acquisition of companies, parts of a company, participations, intellectual property rights, licenses or investments, (2) if the issuance occurs in domestic or international capital markets or through a private placement, (3) following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of 15% of the share capital registered in the commercial register without having submitted to all other shareholders a takeover offer recommended by the Board of Directors, or (4) for the defense of an actual, threatened or potential takeover bid that the Board of Directors, upon consultation with an independent financial adviser retained by it, has not recommended or will not recommend to the shareholders to accept on the basis that the Board of Directors does not find such takeover bid to be (i) financially fair to the shareholders or (ii) in the Company's interest. If the advance subscription rights are neither granted directly nor indirectly by the Board of Directors, the following shall apply:

Article 4c

1. Le capital-actions peut être augmenté, y compris en lien avec une future offre publique d'acquisition, d'un montant maximum de CHF 1'079'954.10 par l'émission de 21'599'082 actions nominatives au plus, d'une valeur nominale de CHF 0.05 chacune, qui doivent être intégralement libérées par l'exercice ou l'exercice obligatoire de droits de conversion, d'échange, d'option, de warrant ou d'autres droits ou obligations similaires pour la souscription d'actions octroyées aux actionnaires ou à des tiers de manière autonome ou en rapport avec des obligations, effets, options, warrants ou autres instruments financiers ou obligations contractuelles de la Société ou de l'une des sociétés du groupe (collectivement, les Instruments Financiers).

2. Le droit de souscription préférentiel des actionnaires est exclu en relation avec l'émission d'actions à l'occasion de l'exercice d'instruments Financiers. Les personnes qui détendront alors de tels Instruments Financiers seront en droit d'acquérir les nouvelles actions émises à l'occasion de la conversion, de l'échange ou de l'exercice d'instruments Financiers. Le Conseil d'Administration détermine les principales conditions des Instruments Financiers.

3. Le Conseil d'Administration est autorisé à limiter ou retirer le droit de souscription préalable des actionnaires en relation avec l'émission d'instruments Financiers par la Société ou une des sociétés du groupe (1) si l'émission a pour but le financement, le refinancement ou le paiement de l'acquisition d'entreprises, de parties d'une entreprise, de participations, de droits de propriété intellectuelle, de licences ou d'investissements, (2) si l'émission a lieu sur les marchés de capitaux nationaux ou internationaux ou par le biais d'un placement privé, (3) si un actionnaire ou un groupe d'actionnaires agissant de concert a acquis ou réuni une participation de plus de 15% du capital-actions inscrit au registre du commerce sans avoir présenté à tous les autres actionnaires une offre publique d'achat dont l'acceptation a été recommandée par le Conseil d'Administration, ou (4) pour se défendre contre une offre publique d'achat hostile présentée, menaçante ou potentielle dont le rejet est, respectivement sera, recommandé par le Conseil d'Administration, après consultation d'un conseiller financier indépendant qu'il aura choisi, dans la mesure où le Conseil d'Administration estime que l'offre publique d'achat n'est pas (i) équitable d'un point de vue financier vis-à-vis des actionnaires ou (ii) dans l'intérêt de la Société. Si le droit de souscription préalable n'est pas accordé, de manière directe ou indirecte, par le Conseil d'Administration, les règles suivantes s'appliquent:
(a) the Financial Instruments shall be issued or entered into at market conditions;
(b) the Financial Instruments may be converted, exchanged or exercised during a maximum period of 10 years from the date of issuance or contract conclusion; and
(c) the conversion, exchange or exercise price of the Financial Instruments shall be set with reference to, and/or shall be subject to change based upon, the valuation of the Company's equity and/or market conditions.

4 The direct or indirect acquisition of the new shares acquired through the exercise of Financial Instruments, as well as any subsequent transfer of such shares, shall be subject to the restrictions of article 6 of these Articles of Association.

Article 5
1 The Company may issue its registered shares in the form of single certificates, global certificates, uncertificated securities within the meaning of article 973c or 973d CO, or intermediated securities. Subject to applicable law, the Company may convert its registered shares from one form into another form at any time and without the approval of the shareholders. The Company shall bear the cost associated with any such conversion.

2 A shareholder has no right to request a conversion of the registered shares issued in one form into another form. Each shareholder may, however, at any time request from the Company a written confirmation of the registered shares held by such shareholder, as reflected in the share register.

3 Intermediated securities based on registered shares of the Company cannot be transferred by way of assignment. A security interest in any such intermediated securities also cannot be granted by way of assignment.

(a) les Instruments Financiers sont émis ou conclus aux conditions du marché;
(b) les Instruments Financiers peuvent être convertis, échangés ou exercés durant une période maximale de 10 ans suivant la date de l'émission ou de la conclusion du contrat; et
(c) le prix de conversion, d'échange ou d'exercice des Instruments Financiers est fixé en prenant en compte, et/ou peut être modifié en fonction, de la valorisation des fonds propres de la Société et/ou des conditions du marché.

4 L'acquisition de nouvelles actions acquises directement ou indirectement par l'exercice d'Instruments Financiers, ainsi que le transfert subséquent de ces actions, sont assujettis aux restrictions à la transmissibilité conformément à l'article 6 des Statuts.

Article 5
1 La Société émet ses actions nominatives sous forme de certificats individuels, de certificats globaux, de droits-valeurs au sens des articles 973c ou 973d CO ou des titres intermédiaires. La Société est libre, dans les limites du droit applicable, en tout temps et sans l'approbation des actionnaires, de convertir ses actions nominatives émises sous l'une des formes ci-dessus, en une autre forme. La Société supporte les coûts d'une telle conversion.

2 Un actionnaire n'a pas le droit de réclamer la conversion d'actions nominatives émises sous une certaine forme en une autre forme. Chaque actionnaire peut toutefois exiger en tout temps que la Société établit une attestation relative aux actions nominatives qu'il détient selon le registre des actions.

3 Les titres intermédiaires fondés sur des actions nominatives de la Société ne peuvent pas être transférés par cession. Il ne peut pas non plus être constitué de sûretés par cession sur ces titres intermédiaires.
Article 6

1 The Company shall maintain, itself or through a third party, a share register for the registered shares that lists the surname and name (the name of the company in case of a legal entity), the address and domicile (the registered office in case of a legal entity) of the shareholders or usufructuaries. A person registered in the share register shall notify the share registrar of any change of address. Until such notification has occurred, all written communications from the Company to persons registered in the share register shall be deemed to have been validly made if sent to the address previously recorded in the share register.

2 Persons acquiring shares shall be registered in the share register as shareholders with voting rights upon their request if they expressly declare to have acquired these shares in their own name and for their own account. Subject to paragraph 4 of this article 6 and article 685 d para. 3 CO, no person or entity shall be registered in the share register as a shareholder with voting rights for, and no person or entity may directly or indirectly, formally, constructively or beneficially own, or otherwise control alone or together with third parties voting rights (whether exercisable or not) with respect to more than 15% of the share capital as set forth in the commercial register as a shareholder with voting rights. This restriction shall also apply to persons or entities who hold some or all of their shares through Nominees (as defined in paragraph 4 of this article 6).

3 Subject to Art. 652b para. 3 CO, this transfer restriction also applies in the case of the acquisition of shares by the exercise of subscription, option and conversion rights. The transfer restriction does not apply to acquisitions by inheritance, division of an estate or matrimonial property law.

Registre des actions, limitations à l'inscription, Nominees

1 La Société ou un tiers mandaté par elle tient un registre des actions qui mentionne le nom et le prénom (la raison sociale pour les personnes morales), l'adresse et le domicile (le siège pour les personnes morales) des propriétaires et des usufruefruitiers. Si une personne inscrite au registre des actions change d'adresse, elle doit le communiquer à la personne en charge de la tenue du registre. Aussi longtemps que cette communication n’a pas eu lieu, toutes les communications écrites de la Société aux personnes inscrites au registre des actions seront valablement envoyées à l'adresse inscrite au registre des actions.

2 Les personnes qui acquièrent des actions sont inscrites dans le registre des actions, à leur demande, comme actionnaires avec droit de vote, pour autant qu’elles déclarent expressément avoir acquis les actions en leur nom et pour leur propre compte. Sous réserve de l’alinéa 4 du présent article 6 et de l'article 685d al. 3 CO, aucune personne physique ou morale ne peut être inscrite au registre des actions comme actionnaire avec droit de vote et aucune personne physique ou morale ne peut détenir, directement ou indirectement, formellement, de fait ou comme ayant droit économique, ou contrôler autrement, seul ou avec des tiers, des droits de vote (exercables ou non), par rapport à plus de 15% du capital-actions inscrit au registre du commerce en tant qu'actionnaire avec droit de vote. Cette restriction s'applique également aux personnes ou entités qui détiennent tout ou partie de leurs actions par l'intermédiaire de Nominees (tels que définis à l'alinéa 4 du présent article 6).

3 Sous réserve de l'art. 652b al. 3 CO, les restrictions au transfert s'appliquent également lors de l'acquisition d'actions dans le cadre de l'exercice d'un droit de souscription, d'option ou de conversion. Les restrictions au transfert ne s'appliquent pas lors d'acquisitions par succession, partage successoral ou en vertu du droit matrimonial.
The Board of Directors may, in its own discretion, register persons who declare in the registration application that they hold the shares as nominees (each, a Nominee) on behalf of third party beneficiaries (each, a Beneficial Owner) in the share register as shareholders with voting rights. If, however, any Beneficial Owner should as a result of such registration being made or upheld, directly or indirectly, formally, constructively or beneficially own, or otherwise control or direct, alone or together with third parties, voting rights (whether exercisable or not) with respect to more than 15% of the share capital as set forth in the commercial register, the Board of Directors may cancel the registration of the Nominee holding shares for the account of such Beneficial Owner with respect to any shares in excess of such limit. The Board of Directors may make the registration with voting rights of the shares held by a Nominee subject to conditions, limitations and reporting requirements or may impose or adjust such conditions, limitations and requirements once registered.

Legal entities and partnerships or other groups of persons or joint owners who are interrelated to one another through capital ownership, voting rights, uniform management or are otherwise linked, as well as individuals or legal entities or partnerships who act in concert or otherwise act in a coordinated manner or acquire shares indirectly, thereby circumventing the restrictions or limits pursuant to paragraph 2 or 4 of this article 6 shall be treated as one single person, entity, Nominee or as a person acquiring shares, as applicable, for purposes of paragraphs 2 and 4 of this article 6.

Le Conseil d'Administration peut, à son entière discrétion, inscrire les personnes qui déclarent dans leur requête d'inscription qu'elles détiennent les actions en tant que nommées (chacun, un Nominee) pour le compte de tiers ayants droit économiques (chacun, un Ayant Droit Economique) en tant qu'actionnaires avec droit de vote. Toutefois, si suite à l'inscription ou à la confirmation de l'inscription, un Ayant Droit Economique détient directement ou indirectement, formellement, de fait ou comme ayant droit économique, ou contrôle ou dirige autrement, seul ou avec des tiers, des droits de vote (exercables ou non) par rapport à plus de 15% du capital-actions inscrit au registre du commerce, le Conseil d'Administration peut annuler l'inscription du Nominee détenant les actions pour le compte d'un tel Ayant Droit Economique pour les actions dépassant cette limite. Le Conseil d'Administration peut soumettre l'inscription avec droit de vote des actions détenues par un Nominee à des conditions, limitations, exigences de rapports ou peut imposer de telles conditions, limitations ou exigences suite à l'inscription. Les personnes morales et communautés de personnes ou autres groupes de personnes ou de copropriétaires qui sont liés par le capital, les droits de vote, la gestion commune ou de toute autre manière, de même que les personnes physiques ou morales ou communautés de personnes qui agissent de concert ou de manière coordonnée ou acquièrent indirectement des actions, et contournent ainsi les restrictions ou limites visées aux alinéas 2 ou 4 du présent article 6 sont traités comme une seule personne, personne morale, Nominee ou comme une personne acquérant des actions, selon le cas, aux fins des alinéas 2 et 4 du présent article 6.
The Board of Directors may grant exceptions from the restrictions or limits pursuant to paragraph 2 or 4 of this article 6 for justified reasons with the majority vote of two thirds of all its members. A justified reason may include the situation where a person extends an offer to purchase with respect to all other shares of the Company, which the Board of Directors, after having consulted an independent financial advisor, recommends to the shareholders.

Shareholders, other than Nominees, already being registered directly or through a Nominee with more than 15% at the time that this article 6 takes effect remain registered with voting rights for such shares. Such privilege may not be transferred by an indirect transfer of shares.

After hearing the registered shareholder or Nominee, the Board of Directors may cancel such person's registration in the share register with retroactive effect as of the date of registration if such registration was made based on false or misleading information or if such information becomes untrue or misleading. The relevant shareholder or Nominee shall be promptly informed of the cancellation.

The Board of Directors shall regulate all details and issue the instructions necessary to ensure compliance with the preceding provisions. The Board of Directors may delegate its duties.

Le Conseil d'Administration peut octroyer des dérogations aux restrictions et limites mentionnées aux alinéas 2 ou 4 du présent article 6 pour des raisons justifiées, à la majorité des deux tiers de l'ensemble de ses membres. Peut aussi être considérée comme une raison justifiée le fait qu'une personne étende une offre d'achat par rapport à l'ensemble des autres actions de la Société et que le Conseil d'Administration, après avoir consulté un conseiller financier indépendant, recommande aux actionnaires d'accepter cette offre.

Les actionnaires autres que les Nominees déjà inscrits directement ou par l'intermédiaire d'un Nominee pour plus de 15% au moment où le présent article 6 entre en vigueur demeurent enregistrés avec droit de vote pour ces actions. Ce privilège ne peut être transféré par un transfert indirect d'actions.

Le Conseil d'Administration peut, après avoir entendu l’actionnaire ou le Nominee, radier du registre des actions l'inscription qui a été faite sur la base d'informations fausses ou trompeuses données par l'acquéreur, ou si les informations deviennent fausses ou trompeuses. L'actionnaire ou le Nominee doit être informé immédiatement de la radiation.

Le Conseil d'Administration règle les détails et prend les mesures nécessaires au respect des dispositions ci-dessus. Le Conseil d'Administration peut déléguer ses tâches.
Exercise of rights

Article 7
1 The Company shall only accept one representative per share.
2 The voting right and the rights associated therewith may be exercised vis-à-vis the Company by a shareholder, usufructuary or Nominee only to the extent that such person is registered in the share register with voting rights.

Section 3

Corporate bodies
A. The General Meeting

Article 8
1 The general meeting of shareholders (the General Meeting) is the supreme corporate body of the Company.
2 The General Meeting shall have the following inalienable powers:
   1. the adoption and amendment of these Articles of Association;
   2. the election of the members of the Board of Directors, the chair of the Board of Directors (the Chair) and the members of the Compensation Committee;
   3. the election of the Auditors;
   4. the election of the independent voting rights representative;
   5. the approval of the annual management report and the consolidated financial statements;
   6. the approval of the annual financial statements as well as the resolution on the allocation of profit shown on the balance sheet, in particular the determination of dividends;

Exercice des droits

Article 7
1 La Société ne reconnaît qu'un représentant par action.
2 Le droit de vote et les droits y relatifs ne peuvent être exercés à l'égard de la Société que par un actionnaire, un usufruitier ou un Nominee uniquement dans la mesure où celui-ci est inscrit avec droit de vote au registre des actions.

Section 3

Organes
A. L'Assemblée Générale

Article 8
1 L'assemblée générale des actionnaires (l'Assemblée Générale) est l'organe suprême de la Société.
2 L'Assemblée Générale a le droit inaliénable:
   1. d'adopter et de modifier les Statuts;
   2. de nommer les membres du Conseil d'Administration, le/la président/e du Conseil d'Administration (le/la Président/e) et les membres du Comité de Rémunération;
   3. de nommer l'Organe de Révision;
   4. de nommer le représentant indépendant;
   5. d'approuver le rapport annuel et les comptes consolidés;
   6. d'approuver les comptes annuels et de déterminer l'emploi du bénéfice résultant du bilan, en particulier de fixer le dividende;
7. the discharge from liability of the members of the Board of Directors and the persons entrusted with management;
8. the approval of the compensation of the Board of Directors and of the executive committee of the Company (the Executive Committee) pursuant to article 26 of these Articles of Association; and
9. the adoption of resolutions on matters that are reserved to the General Meeting by law or these Articles of Association or that are, subject to article 716a CO, submitted to the General Meeting by the Board of Directors.

Article 9
1 The ordinary General Meeting shall be held each year within six months of the close of the financial year of the Company.
2 Extraordinary General Meetings of Shareholders shall be held if
   (a) the Board of Directors or the Auditors deem it necessary;
   (b) so resolved by a General Meeting; or
   (c) shareholders who hold, alone or together, shares representing at least 10% of the share capital so request in writing, indicating the matters to be discussed and the corresponding proposals and, in case of elections, the names of the nominated candidates.

Assemblées générales ordinaires et extraordinaires
Notice

1 Notice of a General Meeting shall be given by the Board of Directors or, if necessary, by the Auditors, no later than 20 calendar days prior to the date of the meeting. Liquidators and representatives of bond-holders are also entitled to call a General Meeting.

2 Notice of the General Meeting shall be given by way of a single announcement in the official means of publication of the Company pursuant to article 35 of these Articles of Association. Registered shareholders may in addition be notified in writing.

3 The annual report, the compensation report and the Auditors’ reports shall be made available for inspection by the shareholders at the registered office of the Company no later than 20 calendar days prior to the ordinary General Meeting. Registered shareholders shall be informed in writing in the notice.

4 The notice shall specify the items on the agenda as well as the proposals of the Board of Directors and the shareholder(s) who requested that a General Meeting be held or an item be included on the agenda and, in the event of elections, the names of the proposed candidates.

Convocation

1 L’Assemblée Générale est convoquée par le Conseil d’Administration ou, si nécessaire, par l’Organe de Révision au plus tard 20 jours calendaires avant le jour de l’assemblée. Les liquidateurs et les représentants de détenteurs d’obligations ont également le droit de convoquer l’Assemblée Générale.

2 La convocation à l’Assemblée Générale a lieu par une annonce unique dans l’organe de publication de la Société selon l’article 35 des Statuts. Les actionnaires inscrits doivent en être informés par écrit dans la convocation.

3 Le rapport de gestion, le rapport de rémunération et les rapports de révision sont mis à la disposition des actionnaires au siège de la Société au plus tard 20 jours calendaires avant l’Assemblée Générale ordinaire. Les actionnaires inscrits doivent en être informés par écrit dans la convocation.

4 La convocation mentionne les objets portés à l’ordre du jour ainsi que les propositions du Conseil d’Administration et du ou des actionnaires qui ont demandé la convocation de l’Assemblée Générale ou l’inscription d’un objet à l’ordre du jour et, en cas d’élections, les noms des candidats proposés.

Article 10

1 Notice of a General Meeting shall be given by the Board of Directors or, if necessary, by the Auditors, no later than 20 calendar days prior to the date of the meeting. Liquidators and representatives of bond-holders are also entitled to call a General Meeting.

2 Notice of the General Meeting shall be given by way of a single announcement in the official means of publication of the Company pursuant to article 35 of these Articles of Association. Registered shareholders may in addition be notified in writing.

3 The annual report, the compensation report and the Auditors’ reports shall be made available for inspection by the shareholders at the registered office of the Company no later than 20 calendar days prior to the ordinary General Meeting. Registered shareholders shall be informed in writing in the notice.

4 The notice shall specify the items on the agenda as well as the proposals of the Board of Directors and the shareholder(s) who requested that a General Meeting be held or an item be included on the agenda and, in the event of elections, the names of the proposed candidates.

Convocation

1 L’Assemblée Générale est convoquée par le Conseil d’Administration ou, si nécessaire, par l’Organe de Révision au plus tard 20 jours calendaires avant le jour de l’assemblée. Les liquidateurs et les représentants de détenteurs d’obligations ont également le droit de convoquer l’Assemblée Générale.

2 La convocation à l’Assemblée Générale a lieu par une annonce unique dans l’organe de publication de la Société selon l’article 35 des Statuts. Les actionnaires inscrits doivent en être informés par écrit dans la convocation.

3 Le rapport de gestion, le rapport de rémunération et les rapports de révision sont mis à la disposition des actionnaires au siège de la Société au plus tard 20 jours calendaires avant l’Assemblée Générale ordinaire. Les actionnaires inscrits doivent en être informés par écrit dans la convocation.

4 La convocation mentionne les objets portés à l’ordre du jour ainsi que les propositions du Conseil d’Administration et du ou des actionnaires qui ont demandé la convocation de l’Assemblée Générale ou l’inscription d’un objet à l’ordre du jour et, en cas d’élections, les noms des candidats proposés.

Article 11

1 Shareholders who, alone or together, either hold shares with a par value of at least CHF 1,000,000 or who represent at least 10% of the share capital may request that an item be included on the agenda. Such request must be made in writing and be received at the registered office of the Company at least 45 calendar days prior to the General Meeting, specifying the agenda item and the proposals of the shareholders.

2 Notice of the General Meeting shall be given by way of a single announcement in the official means of publication of the Company pursuant to article 35 of these Articles of Association. Registered shareholders may in addition be notified in writing.

3 The annual report, the compensation report and the Auditors’ reports shall be made available for inspection by the shareholders at the registered office of the Company no later than 20 calendar days prior to the ordinary General Meeting. Registered shareholders shall be informed in writing in the notice.

4 The notice shall specify the items on the agenda as well as the proposals of the Board of Directors and the shareholder(s) who requested that a General Meeting be held or an item be included on the agenda and, in the event of elections, the names of the proposed candidates.

Convocation

1 L’Assemblée Générale est convoquée par le Conseil d’Administration ou, si nécessaire, par l’Organe de Révision au plus tard 20 jours calendaires avant le jour de l’assemblée. Les liquidateurs et les représentants de détenteurs d’obligations ont également le droit de convoquer l’Assemblée Générale.

2 La convocation à l’Assemblée Générale a lieu par une annonce unique dans l’organe de publication de la Société selon l’article 35 des Statuts. Les actionnaires inscrits doivent en être informés par écrit dans la convocation.

3 Le rapport de gestion, le rapport de rémunération et les rapports de révision sont mis à la disposition des actionnaires au siège de la Société au plus tard 20 jours calendaires avant l’Assemblée Générale ordinaire. Les actionnaires inscrits doivent en être informés par écrit dans la convocation.

4 La convocation mentionne les objets portés à l’ordre du jour ainsi que les propositions du Conseil d’Administration et du ou des actionnaires qui ont demandé la convocation de l’Assemblée Générale ou l’inscription d’un objet à l’ordre du jour et, en cas d’élections, les noms des candidats proposés.

Article 11

1 Shareholders who, alone or together, either hold shares with a par value of at least CHF 1,000,000 or who represent at least 10% of the share capital may request that an item be included on the agenda. Such request must be made in writing and be received at the registered office of the Company at least 45 calendar days prior to the General Meeting, specifying the agenda item and the proposals of the shareholders.

2 Notice of the General Meeting shall be given by way of a single announcement in the official means of publication of the Company pursuant to article 35 of these Articles of Association. Registered shareholders may in addition be notified in writing.

3 The annual report, the compensation report and the Auditors’ reports shall be made available for inspection by the shareholders at the registered office of the Company no later than 20 calendar days prior to the ordinary General Meeting. Registered shareholders shall be informed in writing in the notice.

4 The notice shall specify the items on the agenda as well as the proposals of the Board of Directors and the shareholder(s) who requested that a General Meeting be held or an item be included on the agenda and, in the event of elections, the names of the proposed candidates.
No resolutions may be passed at a General Meeting on proposals concerning agenda items for which proper notice was not given. This provision shall not apply, however, to proposals made during a General Meeting to convene an extraordinary General Meeting or to initiate a special audit. Each request for inclusion of an item on the agenda shall include (i) a brief description of the agenda item and the reason for which it is to be discussed at the meeting; (ii) the motions regarding the agenda item; (iii) the name and address, as they appear on the Company's register of shareholders, of the shareholder proposing such business; (iv) the number of shares of the Company which are beneficially owned by such shareholder; (v) the dates upon which the shareholder acquired such shares; (vi) documentary support for any claim of beneficial ownership; (vii) any material interest of such shareholder in including the item in the agenda; (viii) a statement in support of the matter; and (ix) all other information required under applicable law and stock exchange rules.

No prior notice is required to bring motions related to items already on the agenda or for the discussion of matters on which no resolution is to be taken.

Aucune décision ne peut être prise par l'Assemblée Générale sur des objets qui n'ont pas été dûment portés à l'ordre du jour, à l'exception des propositions de convoquer une Assemblée Générale extraordinaire et d'instituer un contrôle spécial. Toute requête visant l'inscription d'un objet à l'ordre du jour doit inclure (i) une brève description de cet objet et la raison pour laquelle il doit être discuté lors de l'Assemblée Générale; (ii) les propositions relatives à cet objet; (iii) le nom et l'adresse, tels qu'ils apparaissent dans le registre des actions, de l'actionnaire proposant un tel objet; (iv) le nombre d'actions de la Société dont cet actionnaire est l'Ayant Droit Economique; (v) les dates auxquelles l'actionnaire a acquis ces actions; (vi) les pièces justificatives démontrant le statut d'Ayant Droit Economique; (vii) l'intérêt important de l'actionnaire à l'inscription de l'objet à l'ordre du jour; (viii) une déclaration à l'appui de la requête; et (ix) toute autre information requise par la loi ou les règles boursières applicables.

En revanche, il n'est pas nécessaire d'annoncer à l'avance les propositions entrant dans le cadre des objets portés à l'ordre du jour ni les délibérations qui ne doivent pas être suivies d'un vote.
**Article 12**

1. The Chair of the Board of Directors shall chair the General Meeting. In his absence, the Vice-Chair of the Board of Directors, another member or a person designated by the Board of Directors shall chair the General Meeting. If no member of the Board of Directors is available and no other person has been designated by the Board of Directors, the acting chair shall be elected by the General Meeting.

2. The acting chair of the General Meeting shall appoint the secretary and the vote counter(s), none of whom need be shareholders. The minutes shall be signed by the acting chair of the General Meeting of and the secretary.

3. The acting chair of the General Meeting shall have all powers and authority necessary and appropriate to ensure the orderly conduct of the General Meeting.

**Article 13**

1. Each share shall convey the right to one vote. The voting rights are subject to the conditions of articles 6 and 7 of these Articles of Association.

2. No shareholder or proxy may, directly or indirectly, exercise voting rights attached to own or represented shares that would collectively exceed 15% of the share capital as set forth in the commercial register. Legal entities and partnerships or other groups of persons or joint owners who are interrelated to one another through capital ownership, voting rights, uniform management or are otherwise linked, as well as individuals or legal entities or partnerships who act in concert or otherwise act in a coordinated manner, thereby circumventing the aforementioned restriction of voting rights, are deemed to be one shareholder for the purposes of such voting.
The restrictions of paragraph 2 of this article 13 shall not apply to the exercise of voting rights by (i) shareholders or their proxies, to the extent that their shares are registered in the share register with voting rights pursuant to article 6 paragraph 7 of these Articles of Association, (ii) Nominees, provided that Nominees’ voting rights shall be subject to the same restrictions as set forth in article 6 paragraph 4 of these Articles of Association, and (iii) the independent voting rights representative to the extent that the latter has been appointed as proxy by shareholders.

The Board of Directors shall issue the rules regarding the participation in and representation at the General Meeting and determine the requirements as to proxies and instructions. A shareholder may only be represented at the General Meeting by the independent voting rights representative, its legal representative or, by means of a written proxy, by another shareholder with the right to vote. All shares held by a shareholder may only be represented by one person.

The General Meeting shall elect the independent voting rights representative for a term of office until completion of the next ordinary General Meeting. Re-election is possible.

If the Company does not have an independent voting rights representative, the Board of Directors shall appoint the independent voting rights representative for the next General Meeting.

**Article 14**
1 The General Meeting shall pass its resolutions and decide its elections by the absolute majority of the votes attached to the shares represented, unless required otherwise by law or these Articles of Association. In the event of a tie, the resolution shall be deemed refused.
Two thirds of the votes represented and the absolute majority of the par value of shares represented shall be required for the General Meeting to adopt resolutions on the following matters:

1. the amendment of the purpose of the Company;
2. the creation of shares with privileged voting rights;
3. the restriction on the transferability of registered shares or their registration with voting rights and the cancelation of such a restriction;
4. an authorized or conditional increase in share capital;
5. an increase in share capital through the conversion of equity surplus, against contributions in kind or for purposes of an acquisition of assets, or the granting of special benefits;
6. the limitation or withdrawal of pre-emptive rights;
7. the relocation of the registered office of the Company;
8. the dissolution of the Company;
9. mergers, demergers and conversions pursuant to the Swiss federal act on merger, demerger, conversion and transfer of assets and liabilities (the Merger Act);
10. the conversion of registered shares into bearer shares;
11. the removal of any member of the Board of Directors or of its Chair before the end of his/her term of office; and

Une décision de l'Assemblée Générale recueillant au moins les deux tiers des voix attribuées aux actions représentées et la majorité absolue des valeurs nominales représentées est nécessaire pour:

1. la modification du but social de la Société;
2. l'introduction d'actions à droit de vote privilégié;
3. la restriction de la transmissibilité des actions nominatives ou leur inscription avec droit de vote ainsi que la suppression d'une telle restriction;
4. l'augmentation autorisée ou conditionnelle du capital-actions;
5. l'augmentation du capital-actions au moyen de la conversion de fonds propres, contre apport en nature ou en vue d'une reprise de biens et l'octroi d'avantages particuliers;
6. la limitation ou la suppression du droit de souscription préférentiel;
7. le transfert du siège de la Société;
8. la dissolution de la Société;
9. une fusion, scission ou transformation conformément à la loi fédérale sur la fusion, la scission, la transformation et le transfert de patrimoine (la Loi sur la Fusion);
10. la conversion d'actions nominatives en actions au porteur;
11. la révocation de tout membre du Conseil d'Administration ou de son/sa Président/e avant la fin de son mandat; et
12. the amendment or repeal of the following provisions of these Articles of Association, with the exception of editorial amendments that do not effectively change their content:

(i) article 4a paragraph 1, 2, 4(g) and 4(h);
(ii) article 4c paragraph 1, 3 and 4;
(iii) article 6;
(iv) article 13 paragraph 2 and 3;
(v) article 14;
(vi) article 15; and
(vii) article 18.

3 Resolutions and elections shall be decided by open ballot, unless the acting chair of the General Meeting decides that a secret ballot be held or that it be voted by electronic means. The acting chair of the General Meeting may at any time order that a resolution or election be repeated if he/she considers the vote to be in doubt. The resolution or election previously held shall then be deemed not to have taken place.

B. The Board of Directors

Article 15
The board of directors of the Company (the Board of Directors) shall consist of not less than 3 and not more than 8 members.

B. Le Conseil d'Administration

Article 15
Le conseil d'administration de la Société (le Conseil d'Administration) se compose de 3 membres au moins et de 8 membres au plus.
Article 16
1. The General Meeting shall elect the members of the Board of Directors and the Chair of the Board of Directors individually and for a term of office until the completion of the next ordinary General Meeting. Re-election is possible.

2. If the office of the Chair of the Board of Directors is vacant, the Board of Directors shall appoint a new Chair from among its members for a term of office extending until completion of the next ordinary General Meeting.

Article 17
1. Except for the election of the Chair of the Board of Directors and the members of the Compensation Committee by the General Meeting, the Board of Directors shall constitute itself. The Board of Directors may elect one or several vice-chairs (each, a Vice-Chair). The Board of Directors shall further appoint a secretary who need not be member of the Board of Directors.

2. Subject to these Articles of Association, the Board of Directors shall regulate its organization and the adoption of resolutions in the organizational regulations.

Article 16
1. Les membres du Conseil d'Administration et le/la Président/e du Conseil d'Administration sont élus individuellement par l'Assemblée Générale pour une durée de fonctions s'achevant à la fin de l'Assemblée Générale ordinaire suivante. La réélection est possible.

2. Lorsque la fonction de Président/e du Conseil d'Administration est vacante, le Conseil d'Administration désigne un/une nouveau-elle Président/e parmi ses membres pour une durée de fonctions s'achevant à la fin de l'Assemblée Générale ordinaire suivante.

Article 17
1. À l'exception de l'élection par l'Assemblée Générale du/de la Président/e du Conseil d'Administration et des membres du Comité de Rémunération, le Conseil d'Administration se constitue lui-même. Il peut désigner au besoin, un/une ou plusieurs vice-président/e(s) (chacun, un/e Vice-Président/e). Le Conseil d'Administration désigne en outre un/une secrétaire, qui ne doit pas nécessairement être membre du Conseil d'Administration.

2. Le Conseil d'Administration règle en outre son organisation et la manière de prendre des décisions dans un règlement d'organisation, sous réserve des Statuts.
Article 18

1 The members of the Board of Directors shall be entitled to the reimbursement of all expenses incurred in the interest of the Company.

2 To the extent not included in insurance coverage or paid by third parties, the Company shall indemnify and hold harmless, to the extent permitted by law, the existing and former members of the Board of Directors and Executive Committee, and their heirs, executors and administrators, out of the assets of the Company from and against all threatened, pending or completed actions, suits or proceedings – whether civil, criminal, administrative or investigative – and all costs, charges, losses, damages, and expenses which they or any of them, their heirs, executors or administrators, shall or may incur or sustain by or by reason of any actual or alleged actions, consents or omissions in or about the execution of their duty, or alleged duty, or by reason of the fact that he is or was a member of the Board of Directors or Executive Committee of the Company or the board of directors (or equivalent corporate body) or the management of one of its subsidiaries, or, while serving as a member of the Board of Directors or Executive Committee of the Company, is or was serving at the request of the Company as a director, member of the executive management, employee or agent of another corporation, partnership, joint venture, trust or other enterprise; provided, however, that this indemnity shall not extend to any matter in which any of said persons is found, in a final judgment or decree of a court or governmental or administrative authority of competent jurisdiction not subject to appeal, to have committed an intentional or grossly negligent breach of his statutory duties as a member of the Board of Directors or Executive Committee.

3 Without limiting the foregoing paragraph 2 of this article 18, the Company shall advance costs and expenses indemnifiable thereunder to the existing and former members of the Board of Directors and Executive Committee to the extent not included in insurance coverage or advanced by third parties. The Company may however recover such advanced costs if any of said persons is found, in a final judgment or decree of a court or governmental or administrative authority of competent jurisdiction not subject to appeal, to have committed an intentional or grossly negligent breach of his statutory duties as a member of the Board of Directors or Executive Committee.

Reimbursement of expenses, indemnification

1 Les membres du Conseil d’Administration ont droit au remboursement de tous les frais engagés dans l’intérêt de la Société.

2 Dans la mesure où la loi le permet, la Société indemnisera, à concurrence de la portion non couverte par une assurance ou payée par un tiers, sur ses propres biens les membres actuels et passés du Conseil d’Administration et de la Direction Exécutive ainsi que leurs héritiers, masse en faillite ou masse successorale contre toutes actions, procès ou poursuites, menaçants, en cours ou terminés, de nature civile, pénale, administrative ou autre, et tous les coûts, dépenses, pertes, dommages et frais qu’ils (ou leurs héritiers, masse en faillite ou masse successorale) subiraient ou pourraient subir en raison d’actions, consentements ou omissions, effectifs ou présumés, en relation avec l’exercice de leurs fonctions, leurs fonctions supposées ou en raison du fait d’être ou d’avoir été membres du Conseil d’Administration ou de la Direction Exécutive de la Société ou du conseil d’administration (ou d’un organe équivalent) ou de la direction de l’une de ses filiales ou, sur instruction de la Société en tant que membres du Conseil d’Administration ou de la Direction Exécutive, en raison du fait d’être ou d’avoir été administrateur, membre de la direction, employé ou mandataire d’une autre société, entreprise, coentreprise, personne morale dénuée de la personnalité ou trust. L’obligation d’indemnisation s’étend dès qu’un jugement définitif et exécutoire d’un tribunal ou d’une autorité compétente a décidé que la personne en question a violé, volontairement ou par grave négligence, ses devoirs de membre du Conseil d’Administration ou de la Direction Exécutive.

3 Sans préjudice de l’alinéa 2 du présent article 18, la Société avancera les frais et les coûts indemnisables en vertu de la disposition précitée aux membres actuels et passés du Conseil d’Administration et de la Direction Exécutive, à concurrence de la portion non couverte par une assurance ou payée par un tiers. La Société peut cependant recouvrer ces avances de frais si l’une de ces personnes a été reconnue coupable de violation intentionnelle ou par négligence grave de ses devoirs de membre du Conseil d’Administration ou de la Direction Exécutive par un jugement ou une décision final et exécutoire d’un tribunal ou d’une autorité gouvernementale ou administrative compétente.
Article 19

1 The Board of Directors shall meet at the invitation of its Chair or, if not available, of the Vice-Chair or of another member of the Board of Directors as often as the business of the Company shall require or if a member requests it in writing or via telefax, email or another form of electronic communication, indicating the reasons.

2 Unless the organizational regulations adopted by the Board of Directors or a board resolution taken with the applicable attendance quorum provide otherwise, the Board of Directors shall only have a quorum if a majority of the members of the Board of Directors is present. No attendance quorum shall be required for resolutions of the Board of Directors providing for the amendment and ascertainment of a capital increase.

3 Except as otherwise provided in the organizational rules, resolutions of the Board of Directors shall be adopted by the majority of the members present, provided that those present form a majority of the Board of Directors. In case of a tie, the Chair shall not have a casting vote.

4 Resolutions may also be adopted by way of written consent or by approval via email or another form of electronic communication, unless a member of the Board of Directors requests discussion thereof.

5 The decisions of the Board of Directors shall be recorded in minutes. The minutes shall be signed by the acting chair and the secretary.


**Article 20**

1. The Board of Directors may pass resolutions with respect to all matters which are not delegated to another corporate body of the Company by law, by these Articles of Association or by regulations.

2. It shall have the following non-transferable and inalienable duties:
   1. the ultimate management of the Company and the issuance of necessary instructions;
   2. the determination of the organization of the Company;
   3. the structuring of the accounting system, of the financial controls and of the financial planning;
   4. the appointment and dismissal of the persons entrusted with management and representation of the Company, and issuance of rules on the signature authority;
   5. the ultimate supervision of the persons entrusted with management, in particular in view of compliance with the law, these Articles of Association, regulations and directives;
   6. the preparation of the annual report and the compensation report;
   7. the preparation of the General Meeting and the implementation of its resolutions;

---

**Attributions du Conseil d'Administration**

1. Le Conseil d'Administration peut prendre des décisions sur toutes les affaires qui ne sont pas attribuées à un autre organe de la Société par la loi, les Statuts ou un règlement.

2. Il a les attributions intransmissibles et inaliénables suivantes:
   1. exercer la haute direction de la Société et établir les instructions nécessaires;
   2. fixer l'organisation de la Société;
   3. fixer les principes de la comptabilité et du contrôle financier ainsi que le plan financier;
   4. nommer et révoquer les personnes chargées de la gestion et de la représentation de la Société et réglementer le droit de signature;
   5. exercer la haute surveillance sur les personnes chargées de la gestion pour s'assurer notamment qu'elles observent la loi, les Statuts, les règlements et les instructions données;
   6. établir le rapport de gestion et le rapport de rémunération;
   7. préparer l'Assemblée Générale et exécuter ses décisions;
8. the adoption of resolutions on the increase of the share capital to the extent that such power is vested in the Board of Directors, the ascertainment of capital increases, the preparation of the report on the capital increase, and the respective amendments of these Articles of Association (including deletions);

9. the non-transferable and inalienable duties and powers of the Board of Directors pursuant to the Merger Act;

10. the notification of the judge if liabilities exceed assets; and

11. other powers and duties reserved to the Board of Directors by law or these Articles of Association.

3 In all other respects, the Board of Directors may delegate in whole or in part the management and the representation of the Company within the framework set forth by these Articles of Association and the law to one or several of its members or to third parties by means of organizational regulations.

C. The Compensation Committee

Article 21

The compensation committee of the Board of Directors (the Compensation Committee) shall consist of at least 2 members of the Board of Directors.

C. Le Comité de Rémunération

Article 21

Le comité de rémunération du Conseil d'Administration (le Comité de Rémunération) se compose d'au moins 2 membres du Conseil d'Administration.
Article 22
1 The General Meeting shall elect the members of the Compensation Committee individually for a term of office until the completion of the subsequent ordinary General Meeting. Only members of the Board of Directors may be elected. Re-election is possible.
2 If there are vacancies on the Compensation Committee, the Board of Directors may appoint substitute members from among its members for a term of office extending until completion of the next ordinary General Meeting.

Article 23
1 The Compensation Committee shall constitute itself. Unless the organizational regulations provide otherwise, the Board of Directors shall elect a chair from among the Compensation Committee's members.
2 The Board of Directors shall issue regulations establishing the organization and decision-making process of the Compensation Committee, which may be part of the organizational regulations.

Article 24
1 The Compensation Committee shall support the Board of Directors in establishing and reviewing the compensation strategy and guidelines as well as in preparing the proposals to the General Meeting regarding the compensation of the Board of Directors and the Executive Committee. It may submit proposals to the Board of Directors in other compensation-related issues.
2 The Board of Directors shall determine in regulations for which positions of the Board of Directors, the Executive Committee and other member of management (if any) the Compensation Committee shall submit proposals for the performance metrics, target values and/or the compensation of the members of the Board of Directors and the Executive Committee, and for which positions it shall itself determine, in accordance with these Articles of Association and the compensation guidelines established by the Board of Directors, such performance metrics, target values and/or the compensation.

3 The Board of Directors may delegate further tasks to the Compensation Committee.

D. The Auditors

Article 25

1 The General Meeting shall elect the auditors of the Company (the Auditors) for a term of office until the completion of the next ordinary General Meeting. Re-election is possible.

2 The Auditors shall have the powers and duties vested in them by law.

3 The Board of Directors may mandate the Auditors at any time to perform special investigations, in particular interim audits, and to prepare a report on their findings.

2 Le Conseil d'Administration détermine dans un règlement pour quelles fonctions du Conseil d'Administration, de la Direction Exécutive et d'autres membres de la direction (si applicable) le Comité de Rémunération proposera au Conseil d'Administration les mesures de performance, les valeurs cibles et/ou la rémunération des membres du Conseil d'Administration et de la Direction Exécutive, et pour quelles fonctions il aura la compétence de déterminer de son propre chef, en accord avec les Statuts et les directives de rémunération établies par le Conseil d'Administration, les mesures de performance, les valeurs cibles et/ou la rémunération.

3 Le Conseil d'Administration peut déléguer d'autres tâches au Comité de Rémunération.

D. L'Organe de Révision

Article 25

1 L’Assemblée Générale élit l’organe de révision de la Société (l’Organe de Révision) pour une durée de fonctions s’achevant à la fin de l’Assemblée Générale ordinaire suivante. La réélection est possible.

2 L’Organe de Révision a les pouvoirs et obligations que lui confère la loi.

3 Le Conseil d’Administration peut en tout temps charger l’Organe de Révision de procéder à des contrôles spéciaux, notamment des révisions intermédiaires, et de lui en soumettre un rapport.
Article 26

1 The General Meeting shall approve the proposals of the Board of Directors in relation to the aggregate amounts of:

1. the maximum compensation of the Board of Directors until the completion of the next ordinary General Meeting;
2. the maximum fixed compensation of the Executive Committee for the following financial year; and
3. the maximum variable compensation of the Executive Committee for the current financial year.

2 The Board of Directors may submit for approval by the General Meeting deviating, additional or conditional proposals relating to the maximum aggregate amount or maximum partial amounts for the same or different periods and/or specific compensation components and/or in relation to additional amounts for specific compensation components.

3 In the event that the General Meeting does not approve a proposal of the Board of Directors, the Board of Directors shall determine, taking into account all relevant factors, the respective (maximum) aggregate amount or (maximum) partial amounts, and submit the amount(s) so determined for approval by a General Meeting.

4 The Company or companies controlled by it may pay or grant compensation prior to approval by the General Meeting, subject to subsequent approval.
Article 27
If the maximum aggregate amount of compensation already approved by the General Meeting is not sufficient to also cover the compensation of one or more persons who become members of the Executive Committee or are being promoted within the Executive Committee after the General Meeting has approved the compensation of the Executive Committee for the relevant period, then the Company or companies controlled by it shall be authorized to pay such member(s) a supplementary amount during the compensation period(s) already approved. The supplementary amount per compensation period per member shall not exceed 100% of the aggregate amount of (maximum) compensation of the Executive Committee last approved.

Article 28
1 The compensation of the non-executive members of the Board of Directors may consist of fixed and variable compensation elements. Total compensation shall take into account the position and level of responsibility of the recipient.
2 The compensation of the members of the Executive Committee may consist of fixed and variable compensation elements. Fixed compensation comprises the base salary and may consist of other compensation elements. Variable compensation may take into account the achievement of specific performance targets. Total compensation shall take into account the position and level of responsibility of the recipient.
3 The performance targets may include individual targets, targets of the Company, group or parts thereof or targets in relation to the market, other companies or comparable benchmarks, taking into account the position and level of responsibility of the recipient. The Board of Directors or, to the extent delegated to it, the Compensation Committee shall determine the relative weight of the performance targets and the respective target values.
Compensation may be paid in the form of cash, shares, options or other share-based instruments or units, or in the form of other types of benefits. The Board of Directors or, to the extent delegated to it, the Compensation Committee shall determine grant, vesting, exercise, restriction and forfeiture conditions and periods. In particular, they may provide for continuation, acceleration or removal of vesting, exercise, restriction and forfeiture conditions and periods, for payment or grant of compensation based upon assumed target achievement, or for forfeiture, in each case in the event of predetermined events such as a change of control or termination of an employment or mandate agreement. The Company may procure the required shares or other securities through purchases in the market, from treasury shares or by using conditional or authorized share capital.

The Company or companies controlled by it.

**Article 29**

1. The Company or companies controlled by it may enter into agreements with non-executive members of the Board of Directors relating to their compensation for a fixed term or for an indefinite term. The duration and termination are subject to the term of office and the law.

2. The Company or companies controlled by it may enter into employment agreements with executive members of the Board of Directors and other members of the Executive Committee for a fixed term or for an indefinite term. Fixed term agreements may have a maximum duration of one year; renewal is possible. Agreements for an indefinite term may have a notice period of maximum twelve months.

3. The Company or companies controlled by it may enter into non-compete agreements with members of the Executive Committee for the time after termination of employment. Their duration shall not exceed two years, and consideration paid per year for such non-compete undertaking shall not exceed the sum of the total annual compensation of such member last paid or payable for the first time.

La rémunération peut être versée en espèces, sous forme d'actions, d'options ou d'instruments ou unités sur base d'actions ou d'autres types de prestations. Le Conseil d'Administration ou le Comité de Rémunération, dans la mesure où cette compétence lui a été déléguée, détermine les conditions et périodes d'octroi, d'acquisition (vesting), d'exercice, de restriction et de pérémption. Ils peuvent en particulier prévoir la continuation, l'accélération ou la suppression des conditions ou périodes d'acquisition (vesting), d'exercice, de restriction et de pérémption, le versement ou l'octroi d'une rémunération supposant l'atteinte des objectifs ou encore la déchéance des droits, dans chaque cas lors d'événements prédéterminés tels que, notamment, un changement de contrôle ou la fin d'un contrat de travail ou de mandat. La Société peut se procurer les actions ou autres instruments des marchés financiers requis par le biais d'achats sur le marché ou d'actions propres, ou en utilisant son capital-actions conditionnel ou autorisé.

La rémunération peut être versée par la Société ou tout autre société qu'elle contrôle.
Article 30

1 The number of mandates on the Board of Directors or the Executive Committee of legal entities that have to be registered in a Swiss commercial register or a similar foreign register outside the group is limited:

(a) for members of the Executive Committee, to 7 mandates, of which no more than 2 in a listed company; and

(b) for members of the Board of Directors, to 15 mandates, of which no more than 5 in listed companies.

2 Mandates in different legal entities being part of the same group or for the same group are deemed to be one mandate.

3 Mandates in associations, charitable organizations, family trusts and foundations relating to post-retirement benefits are not subject to the above limitations. No member of the Board of Directors or the Executive Committee shall hold more than 10 such mandates.

Article 31

The Company or companies controlled by it may grant to members of the Board of Directors and the Executive Committee post-retirement benefits beyond the occupational benefit schemes which do not exceed the annual compensation of the respective member of the Board of Directors or the Executive Committee last paid or payable for the first time.

Mandats en dehors du groupe

1 Le nombre de mandats d'administrateur et/ou au sein de la Direction Exécutive d'entités juridiques tenues d'être inscrites au registre du commerce suisse ou dans un registre similaire étranger est limité:

(a) pour les membres de la Direction Exécutive, à 7 mandats, dont pas plus de 2 au sein de sociétés cotées; et

(b) pour les membres du Conseil d'Administration à 15 mandats, dont pas plus de 5 au sein de sociétés cotées.

2 Les mandats dans différentes entités juridiques appartenant au même groupe ou assumés pour le même groupe sont considérés comme un mandat.

3 Les mandats dans des associations, organisations caritatives, fondations de famille et fondations de prévoyance professionnelle ne sont pas soumis aux limites mentionnées ci-dessus. Aucun membre du Conseil d'Administration ou de la Direction Exécutive ne peut exercer plus de 10 mandats de ce genre.

Article 31

La Société ou toute société qu'elle contrôle peut octroyer aux membres du Conseil d'Administration et de la Direction Exécutive des prestations de retraite allant au-delà du régime de prévoyance professionnelle n'excédant pas la rémunération annuelle du membre du Conseil d'Administration ou de la Direction Exécutive concerné versée ou à verser pour la première fois.
Section 5  
Financial year, profit allocation

Article 32
1 The Company’s financial year shall be determined by the Board of Directors.

2 The Board of Directors shall prepare an annual report for each financial year, comprising the annual financial statements, if required, the management report and the consolidated financial statements, as well as a compensation report.

Article 33
1 The General Meeting shall resolve on the allocation of the profit as shown on the balance sheet in accordance with applicable law. The Board of Directors shall submit its proposals to the General Meeting.
2 In addition to the reserves required by law, the General Meeting may create other reserves.
3 Dividends that have not been collected within five years after their payment date shall inure to the Company and be allocated to the general statutory reserves.

Section 6  
Dissolution, liquidation

Article 34
1 The General Meeting may at any time resolve to dissolve and liquidate the Company in accordance with the law and the provisions set forth in these Articles of Association.
2 The liquidation shall be effected by the Board of Directors, unless the General Meeting appoints other persons as liquidators.
3 The liquidation of the Company shall be effected pursuant to applicable law. The liquidators shall be entitled to sell assets (real estate included) in private transactions.
4 Upon discharge of all liabilities of the Company, the assets shall be distributed to the shareholders in proportion to the share capital, unless these Articles of Association provide otherwise.
Section 7
Notices, communications

Article 35
1 The official means of publication of the Company shall be the Swiss Official Gazette of Commerce.

2 To the extent that personal notification is not mandated by law, all communications to the shareholders shall be deemed valid if published in the Swiss Official Gazette of Commerce. Written communications by the Company to its shareholders shall be sent by ordinary mail to the last address of the shareholder or authorized recipient entered in the share register. If neither these Articles of Association nor the law mandatorily require a communication to be in written form, the Company can validly send communications to the shareholders to the last email address of the shareholder or authorized recipient communicated to the Company, through the banking system, electronically, by publication in the Swiss Official Gazette of Commerce or in any other way. To comply with the written form, a facsimile or electronic copy of a signature shall be sufficient.

Section 8
Authoritative language

Article 36
In the event of discrepancies between the French and English versions of these Articles of Association, the French version shall prevail.

Section 7
Communications, organe de publication

Article 35
1 L’organe de publication de la Société est la Feuille Officielle Suisse du Commerce.

2 Dans la mesure où la loi n'exige pas de notification personnelle, toutes les communications aux actionnaires publiées dans la Feuille Officielle Suisse du Commerce seront réputées valides. Les communications écrites adressées par la Société à ses actionnaires seront envoyées par courrier ordinaire à la dernière adresse de l’actionnaire ou de son bénéficiaire autorisé qui figure sur le registre des actions. Si ni la loi ni les Statuts n'imposent qu'une communication revête la forme écrite, la Société peut valablement envoyer une telle communication aux actionnaires par email, à la dernière adresse email de l'actionnaire ou de son bénéficiaire autorisé communiquée à la Société, par l'intermédiaire du système bancaire, électroniquement, par publication dans la Feuille Officielle Suisse du Commerce ou de toute autre manière. Une copie ou une copie électronique de la signature suffisent pour se conformer à la forme écrite.

Langue faisant foi

Article 36
En cas de conflit entre la version française et la version anglaise, la version française des Statuts prévaut.

Saint-Sulpice, le 15 juin 2022

31 / 31
SOPHiA GENETICS Publishes Results of 2022 Annual General Meeting

BOSTON, United States and LAUSANNE, Switzerland, June 15, 2022 — SOPHiA GENETICS SA (Nasdaq: SOPH) (“the Company”), is pleased to announce the Annual General Meeting (“the Meeting”) was held at the Company’s headquarters, rue du Centre 172, 1025 St-Sulpice, VD, Switzerland, earlier today at 2:00 p.m. CET (8:00 a.m. EDT).

The Company’s shareholders approved each agenda item presented at the Meeting. The Meeting minutes and detailed voting results by agenda item have been published on the Company’s website in the investor section. The detailed voting results will also be filed with the U.S. Securities and Exchange Commission on a Report on Form 6-K.

Additionally, the Company would like to welcome the newly appointed director, Jean-Michel Cosséry to its Board of Directors. Mr. Cosséry will be a strong addition to the Board of Directors, as he offers more than 25-years of industry experience. The Company looks forward to Mr. Cosséry’s future contributions.

The Company would also like to thank all shareholders represented or having voted by mail or online for their valued commitment and support.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by over 790 hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHIAGENETICS.COM, or connect on Twitter, LinkedIn and Instagram. Where others see data, we see answers.

SOPHiA GENETICS Forward-Looking Statements

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this document speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investor Contact
Jennifer Pottage
Head of Investor Relations
Jpottage@sophiagenetics.com

Media Contact
Don Granese
Public Relations
Dgranese@sophiagenetics.com